微小RNA-122联合APACHEⅡ评分对急性呼吸窘迫综合征患者的预后价值
该研究纳入2016年1月至2018年12月海口市第三人民医院收治的142例ARDS患者,收集24小时内血清miR-122表达水平和APACHEⅡ评分,按生存状态分为生存组和死亡组,按APACHEⅡ评分分为低危组(<10分)、中危组(10-20分)和高危组(>20分)。死亡组血清miR-122(2-ΔΔCt:0.26±0.12 vs. 0.07±0.03)和APACHEⅡ评分(31.84±4.25 vs. 15.30±2.60)均显著高于生存组(均P<0.01)。随着病情严重程度增加,miR-122、APACHEⅡ评分和病死率逐渐升高。ROC曲线显示miR-122联合APACHEⅡ评分预测死亡的AUC为0.918(95%CI=0.857-0.972),高于单独miR-122(AUC=0.835,95%CI=0.776-0.893)和单独APACHEⅡ评分(AUC=0.790,95%CI=0.732-0.854)(均P<0.05),敏感度和特异度分别为91.3%和86.4%。
要点
- 142例ARDS患者中死亡55例、生存87例,死亡组血清miR-122(2-ΔΔCt:0.26±0.12 vs. 0.07±0.03)和APACHEⅡ评分(31.84±4.25 vs. 15.30±2.60)均显著高于生存组(均P<0.01)。
- 随APACHEⅡ评分升高,低危组(<10分)、中危组(10-20分)、高危组(>20分)的miR-122(2-ΔΔCt)分别为0.05±0.02、0.14±0.06、0.23±0.09,病死率分别为11.1%、31.2%、55.2%(均P<0.05)。
- miR-122联合APACHEⅡ评分预测ARDS患者死亡的AUC为0.918(95%CI=0.857-0.972),高于单独miR-122(AUC=0.835,95%CI=0.776-0.893)和单独APACHEⅡ评分(AUC=0.790,95%CI=0.732-0.854)(均P<0.05)。
- 联合预测的敏感度和特异度分别为91.3%和86.4%。
- 死亡ARDS患者血清miR-122表达与APACHEⅡ评分呈正相关(r=0.825,P<0.01)。
适用人群与场景
- 2016年1月至2018年12月海口市第三人民医院收治的ARDS患者,共142例,男94例、女48例,年龄(56.80±11.30)岁。
诊断标准与关键阈值
- 按APACHEⅡ评分分组:低危组<10分,中危组10-20分,高危组>20分。
研究设计与关键结果
- 研究类型为单中心队列研究,纳入142例ARDS患者,死亡55例、生存87例;高危组67例、中危组48例、低危组27例。
- 死亡组血清miR-122(2-ΔΔCt)为0.26±0.12,高于生存组的0.07±0.03;死亡组APACHEⅡ评分为31.84±4.25,高于生存组的15.30±2.60(均P<0.01)。
- 低危组、中危组、高危组的血清miR-122(2-ΔΔCt)分别为0.05±0.02、0.14±0.06、0.23±0.09,APACHEⅡ评分分别为12.30±2.15、20.62±3.40、28.90±3.60,病死率分别为11.1%、31.2%、55.2%(均P<0.05)。
- ROC曲线分析显示,miR-122预测死亡的AUC为0.835(95%CI=0.776-0.893),APACHEⅡ评分为0.790(95%CI=0.732-0.854)。
- miR-122联合APACHEⅡ评分预测死亡的AUC为0.918(95%CI=0.857-0.972),高于单独miR-122和单独APACHEⅡ评分(均P<0.05),敏感度和特异度分别为91.3%和86.4%。
- 死亡ARDS患者血清miR-122表达与APACHEⅡ评分呈正相关(r=0.825,P<0.01)。
证据类型、等级与局限
- 证据类型:单中心队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,血清miR-122表达水平升高与ARDS患者病情严重程度和预后相关。
- 作者认为,miR-122联合APACHEⅡ评分对ARDS患者预后有较高的评估价值。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVE: To investigate the prognostic value of microRNA-122 (miR-122) combined with acute physiology and chronic health evaluation II (APACHE II) score in patient with acute respiratory distress syndrome (ARDS), and to provide evidence for the diagnosis and treatment of ARDS.
METHODS: ARDS patients admitted to the Third People's Hospital of Haikou City from January 2016 to December 2018 were enrolled. The general data, serum miR-122 expression level and APACHE II score within 24 hours were collected. The patients were divided into survival group and death group according to the survival status of ARDS patients. ARDS patients were divided into low-risk group (< 10 scores), medium-risk group (10-20 scores) and high-risk group (> 20 scores) according to APACHE II score. Predictive values of miR-122 and APACHE II scores on prognosis in ARDS patients were evaluated by the receiver operating characteristic (ROC) curve. The correlation between the serum miR-122 expression and APACHE II score in patients with ARDS was calculated by Pearson correlation analysis.
RESULTS: A total of 142 ARDS patients were selected, 94 male and 48 female; with age (56.80±11.30) years old; 55 deaths and 87 survivors; 67 of high-risk, 48 of medium-risk and 27 of low-risk. The expression of serum miR-122 and APACHE II score in the death group were significantly higher than those in the survival group [miR-122 (2-ΔΔCt): 0.26±0.12 vs. 0.07±0.03, APACHE II: 31.84±4.25 vs. 15.30±2.60, both P < 0.01]. With the severity increase of the disease, the serum miR-122 expression level, APACHE II score, and mortality rate of ARDS patients gradually elevated, and the difference between the two groups was significant in the low-risk group, medium-risk group, and high-risk group [miR-122 (2-ΔΔCt): 0.05±0.02, 0.14±0.06, 0.23±0.09; APACHE II: 12.30±2.15, 20.62±3.40, 28.90±3.60; mortality rate: 11.1%, 31.2%, 55.2%, respectively, all P < 0.05]. ROC curve analysis showed that miR-122 and APACHE II score could predict the death of ARDS patients, and the area under the ROC curve (AUC) was 0.835 [95% confidence interval (95%CI) = 0.776-0.893] and 0.790 (95%CI = 0.732-0.854); the predicted value of the miR-122 combined with APACHE II score (AUC = 0.918, 95%CI = 0.857-0.972) was higher than the single miR-122 and APACHE II score (both P < 0.05), with sensitivity and specificity were 91.3% and 86.4% respectively. The correlation analysis showed that the expression of serum miR-122 was positively correlated with APACHE II score in death patient with ARDS (r = 0.825, P < 0.01).
CONCLUSIONS: Elevated serum miR-122 expression level is associated with disease severity and prognosis of ARDS patients; miR-122 combination with APACHE II score has a high evaluation value on prognosis of ARDS patients.
参考来源
- Hao J, Xu J, Liang Y, et al. [Prognostic value of microRNA-122 combined with APACHE II score in patient with acute respiratory distress syndrome]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2019. PMID: 31315725. doi:10.3760/cma.j.issn.2095-4352.2019.06.007
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。